Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | Director | August 01, 2026 | August 04, 2026 |
| Kodiak Sciences Inc.KOD · Entity 4388 | Director | June 30, 2026 | July 02, 2026 |
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director | June 17, 2026 | June 18, 2026 |
| Neurogene Inc.AQXP · Entity 5160 | Director | March 23, 2017 | March 27, 2017 |
| Protara Therapeutics, Inc.TARA · Entity 6203 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date August 01, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 22,359 |
Reported balance
After 2026-08-01 transaction · row 1
1 source rowRow 1 · 2026-08-01 · Exercise / conversion · Acquired 403 · Balance 22,359 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 403 |
Reported balance
After 2026-08-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-01 · Grant · Acquired 403 · Balance 403 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vested immediately upon grant on August 1, 2026; there was no expiration date for the RSUs. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-01 · Exercise / conversion · Disposed 403 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vested immediately upon grant on August 1, 2026; there was no expiration date for the RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vested immediately upon grant on August 1, 2026; there was no expiration date for the RSUs.
Kodiak Sciences Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.96 · Expires 2036-06-29 | Direct | 17,731 |
Reported balance
After 2026-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 17,731 · Balance 17,731 F1: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date.
MADRIGAL PHARMACEUTICALS, INC.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,469 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 454 · Balance 22,469 F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $499.86 · Expires 2036-06-17 | Direct | 766 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 766 · Balance 766 F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
F2: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.
Neurogene Inc.
Report date March 23, 2017 · Filed March 27, 2017
This filing explicitly reported no securities owned.
Protara Therapeutics, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-14 | Direct | 31,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 31,000 · Balance 31,000 F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CONSTELLATION PHARMACEUTICALS INC
Report date July 15, 2021 · Filed July 19, 2021
Section 16 reporting ended · disclosed 2021-07-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.57 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.29 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-15 · Disposition to issuer · Disposed 26,342 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2025 Filed Jul 3, 2025 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,101 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-019334 · form4-07032025_080736.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:43 UTC | Kodiak Sciences Inc. KOD · Entity 4388 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.73 | $0.00 |
DisclosureSEC source: 0001415889-25-019086 · form4-07022025_080755.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-29 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2026 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 20:42 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 1,290 | $0.00 Strike: $285.73 | $0.00 |
DisclosureSEC source: 0001628280-25-032861 · wk-form4_1750797744.xml · derivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,290 Underlying: Common Stock · 1,290 shares Expires 2035-06-20 F2 · derivative.exercise_date: The option vests as to 100% of underlying shares on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided that the Reporting Person continues to serve as a director of the Issuer until such date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 20:42 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 715 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-032861 · wk-form4_1750797744.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,197 F1 · kind: Represents a grant of restricted stock units, which vest on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001213900-25-054285 · marketforms-69815.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 05, 2025 Filed Jun 5, 2025 21:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 3,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015800 · form4-06052025_090611.xml · derivative · entry 4 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 3,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vested in a single installment on June 5, 2025; there was no expiration date for the RSUs. F4 · derivative.expiration_date: The RSUs vested in a single installment on June 5, 2025; there was no expiration date for the RSUs. Read SEC document |
| June 05, 2025 Filed Jun 5, 2025 21:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 3,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-015800 · form4-06052025_090611.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 2,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-015800 · form4-06052025_090611.xml · derivative · entry 3 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,799 Underlying: Class A Ordinary Shares · 2,799 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025. F3 · derivative.expiration_date: The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:05 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 16,798 | $0.00 Strike: $29.11 | $0.00 |
DisclosureSEC source: 0001415889-25-015800 · form4-06052025_090611.xml · derivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,798 Underlying: Class A Ordinary Shares · 16,798 shares Expires 2035-06-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is June 3, 2025. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | PurchaseCommon Stock | 20,000 | $3.19 | $63,800.00 |
DisclosureSEC source: 0001213900-25-044871 · marketforms-69472.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.15 to $3.22, inclusive. The reporting person undertakes to provide to TARA, any security holder of TARA, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 14, 2025 Filed May 19, 2025 20:10 UTC Amendment | Protara Therapeutics, Inc. TARA · Entity 6203 | PurchaseCommon Stock | 20,000 | $3.19 | $63,800.00 |
DisclosureSEC source: 0001213900-25-045399 · marketforms-69540.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.15 to $3.22, inclusive. The reporting person undertakes to provide to TARA, any security holder of TARA, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:59 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,470 | $0.00 Strike: $65.06 | $0.00 |
DisclosureSEC source: 0001628280-25-017563 · wk-form4_1744405167.xml · derivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,470 shares Expires 2025-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:59 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 9,470 | $65.06 | $616,118.20 |
DisclosureSEC source: 0001628280-25-017563 · wk-form4_1744405167.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 22:07 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0000950170-24-124232 · ownership.xml · derivative · entry 3 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2026-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 22:07 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 5,000 | $350.00 | $1,750,000.00 |
DisclosureSEC source: 0000950170-24-124232 · ownership.xml · nonDerivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,012 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023. Read SEC document |
| November 07, 2024 Filed Nov 8, 2024 22:07 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 5,000 | $7.36 | $36,800.00 |
DisclosureSEC source: 0000950170-24-124232 · ownership.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 1,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-026617 · form4-11122024_091100.xml · derivative · entry 3 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 1,303 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vested immediately upon grant on November 7, 2024; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The RSUs vested immediately upon grant on November 7, 2024; there was no expiration date for the RSUs. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 1,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-026617 · form4-11122024_091100.xml · derivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,303 Underlying: Class A Ordinary Shares · 1,303 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vested immediately upon grant on November 7, 2024; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The RSUs vested immediately upon grant on November 7, 2024; there was no expiration date for the RSUs. Read SEC document |
| November 07, 2024 Filed Nov 12, 2024 21:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,303 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-026617 · form4-11122024_091100.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| November 01, 2024 Filed Nov 6, 2024 00:01 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0000950170-24-121722 · ownership.xml · derivative · entry 6 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2026-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document |
| November 01, 2024 Filed Nov 6, 2024 00:01 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 300 | $304.29 | $91,287.30 |
DisclosureSEC source: 0000950170-24-121722 · ownership.xml · nonDerivative · entry 5 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,012 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $303.99 to $304.55, inclusive. Read SEC document |
| November 01, 2024 Filed Nov 6, 2024 00:01 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 800 | $302.25 | $241,799.04 |
DisclosureSEC source: 0000950170-24-121722 · ownership.xml · nonDerivative · entry 4 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,312 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $302.11 to $302.30, inclusive. Read SEC document |
| November 01, 2024 Filed Nov 6, 2024 00:01 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,100 | $301.22 | $331,339.03 |
DisclosureSEC source: 0000950170-24-121722 · ownership.xml · nonDerivative · entry 3 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,112 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $301.00 to $301.76, inclusive. Read SEC document |
| November 01, 2024 Filed Nov 6, 2024 00:01 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,800 | $300.10 | $840,278.04 |
DisclosureSEC source: 0000950170-24-121722 · ownership.xml · nonDerivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,212 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $300.00 to $300.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| November 01, 2024 Filed Nov 6, 2024 00:01 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 5,000 | $7.36 | $36,800.00 |
DisclosureSEC source: 0000950170-24-121722 · ownership.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2024 Filed Jul 1, 2024 22:23 UTC | Kodiak Sciences Inc. KOD · Entity 4388 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001415889-24-018661 · form4-07012024_100759.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-06-27 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 28, 2025 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. Read SEC document |
| June 25, 2024 Filed Jun 28, 2024 01:42 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 1,105 | $0.00 Strike: $280.04 | $0.00 |
DisclosureSEC source: 0000950170-24-078749 · ownership.xml · derivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,105 Underlying: Common Stock · 1,105 shares Expires 2031-06-25 F2 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
| June 25, 2024 Filed Jun 28, 2024 01:42 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 714 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-078749 · ownership.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,012 F1 · shares: Represents a grant of restricted stock units, which vest on June 25, 2025, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 22:00 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001213900-24-051378 · marketforms-66261.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-06 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 4,373 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016006 · form4-06072024_080609.xml · derivative · entry 4 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 4,373 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The RSUs vested in a single installment on June 6, 2024; there was no expiration date for the RSUs. F4 · derivative.expiration_date: The RSUs vested in a single installment on June 6, 2024; there was no expiration date for the RSUs. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 4,373 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-016006 · form4-06072024_080609.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 3,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016006 · form4-06072024_080609.xml · derivative · entry 3 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,173 Underlying: Class A Common Shares · 3,173 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary date of the grant, June 5, 2024. F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary date of the grant, June 5, 2024. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 19,040 | $0.00 Strike: $19.71 | $0.00 |
DisclosureSEC source: 0001415889-24-016006 · form4-06072024_080609.xml · derivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,040 Underlying: Class A Common Shares · 19,040 shares Expires 2034-06-04 F2 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 5, 2024. Read SEC document |
| May 03, 2024 Filed May 7, 2024 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 747 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012480 · form4-05072024_080507.xml · derivative · entry 3 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 747 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vested immediately upon grant on May 3, 2024; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The RSUs vested immediately upon grant on May 3, 2024; there was no expiration date for the RSUs. Read SEC document |
| May 03, 2024 Filed May 7, 2024 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 747 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012480 · form4-05072024_080507.xml · derivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 747 Underlying: Class A Common Shares · 747 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vested immediately upon grant on May 3, 2024; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The RSUs vested immediately upon grant on May 3, 2024; there was no expiration date for the RSUs. Read SEC document |
| May 03, 2024 Filed May 7, 2024 20:46 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 747 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-012480 · form4-05072024_080507.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:47 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $111.06 | $0.00 |
DisclosureSEC source: 0000950170-24-041528 · ownership.xml · derivative · entry 10 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2025-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:47 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0000950170-24-041528 · ownership.xml · derivative · entry 9 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires 2026-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:47 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 300 | $267.07 | $80,121.99 |
DisclosureSEC source: 0000950170-24-041528 · ownership.xml · nonDerivative · entry 8 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,298 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.73 to $267.25, inclusive. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:47 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 713 | $265.28 | $189,145.28 |
DisclosureSEC source: 0000950170-24-041528 · ownership.xml · nonDerivative · entry 7 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,598 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $264.65 to $265.64, inclusive. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:47 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 100 | $259.07 | $25,907.00 |
DisclosureSEC source: 0000950170-24-041528 · ownership.xml · nonDerivative · entry 6 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,311 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:47 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,600 | $257.93 | $412,695.52 |
DisclosureSEC source: 0000950170-24-041528 · ownership.xml · nonDerivative · entry 5 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,411 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $257.54 to $258.465, inclusive. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:47 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 3,900 | $256.88 | $1,001,835.90 |
DisclosureSEC source: 0000950170-24-041528 · ownership.xml · nonDerivative · entry 4 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,011 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $256.45 to $257.40, inclusive. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:47 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 4,387 | $255.90 | $1,122,628.91 |
DisclosureSEC source: 0000950170-24-041528 · ownership.xml · nonDerivative · entry 3 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,911 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $255.42 to $256.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:47 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 6,000 | $111.06 | $666,360.00 |
DisclosureSEC source: 0000950170-24-041528 · ownership.xml · nonDerivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:47 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 5,000 | $7.36 | $36,800.00 |
DisclosureSEC source: 0000950170-24-041528 · ownership.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2023 Filed Nov 7, 2023 21:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Units · Derivative | 2,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-014841 · form4-11072023_091100.xml · derivative · entry 3 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 2,777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vested immediately upon grant on November 3, 2023; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The RSUs vested immediately upon grant on November 3, 2023; there was no expiration date for the RSUs. Read SEC document |
| November 03, 2023 Filed Nov 7, 2023 21:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 2,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-014841 · form4-11072023_091100.xml · derivative · entry 2 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,777 Underlying: Class A Common Shares · 2,777 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vested immediately upon grant on November 3, 2023; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The RSUs vested immediately upon grant on November 3, 2023; there was no expiration date for the RSUs. Read SEC document |
| November 03, 2023 Filed Nov 7, 2023 21:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 2,777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-014841 · form4-11072023_091100.xml · nonDerivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 20:26 UTC | Kodiak Sciences Inc. KOD · Entity 4388 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $6.90 | $0.00 |
DisclosureSEC source: 0001209191-23-040585 · doc4.xml · derivative · entry 1 Levy Richard S · CIK 0001454983 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-29 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2024 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.